""CVac immunotherapy is an autologous dendritic cell-based cancer therapy based on the same technology as Dendreon?s Provenge. The approval of Provenge for asymptomatic or minimally symptomatic metastatic, hormone-refractory prostate cancer, validates the underlying concept. Like Provenge,, CVac? utilizes activated dendritic cells to stimulate a cellular immune response rather than just an antibody response, which we believe is a key differentiating element resulting in a greater likelihood of success. As CVac? advances through its pivotal trial, the Company will likely gain greater visibility among investors. With success, the upside could be enormous: Dendreon has a market capitalization close to $5 billion following approval of Provenge, approximately 30x greater than Prima BioMed.""
http://www.primabiomed.com.au/investor/
more good news, page-3
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $501.1M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.5¢ | 33.5¢ | $1.172M | 3.429M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 29990 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 174098 | 8 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |